Δημοσίευση

Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis.

ΤίτλοςAdministration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis.
Publication TypeJournal Article
Year of Publication2011
AuthorsLourbopoulos, A., Grigoriadis N., Lagoudaki R., Touloumi O., Polyzoidou E., Mavromatis I., Tascos N., Breuer A., Ovadia H., Karussis D., Shohami E., Mechoulam R., & Simeonidou C.
JournalBrain Res
Volume1390
Pagination126-41
Date Published2011 May 16
ISSN1872-6240
Λέξεις κλειδιάAcute Disease, Animals, Arachidonic Acids, Chronic Disease, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Endocannabinoids, Female, Glycerides, Mice, Mice, Inbred C57BL, Random Allocation
Abstract

BACKGROUND AND PURPOSE: Experimental autoimmune encephalomyelitis (EAE) is a widely used model of multiple sclerosis (MS) and both conditions have been reported to exhibit reduced endocannabinoid activity. The purpose of this study was to address the effect of exogenously administered 2-arachidonoylglycerol (2AG), an endocannabinoid receptor ligand, on acute phase and chronic disability in EAE.EXPERIMENTAL APPROACH: Acute and chronic EAE models were induced in susceptible mice and 2AG-treatment was applied for 14 days from day of disease induction.KEY RESULTS: 2AG-treatment ameliorated acute phase of disease with delay of disease onset in both EAE models and reduced disease mortality and long-term (70 days post-induction) clinical disability in chronic EAE. Reduced axonal pathology in the chronic EAE- (p<0.0001) and increased activation and ramification of microglia in the 2AG-treated acute EAE- (p<0.05) model were noticed. The latter was accompanied by a 2- to 4-fold increase of the M2-macrophages in the perivascular infiltrations (p<0.001) of the 2AG-treated animals in the acute (day 22), although not the chronic (day 70), EAE model. Expression of cannabinoid receptors 1 (CB1R) and 2 (CB2R) was increased in 2AG-treated animals of acute EAE vs. controls (p<0.05). In addition, ex vivo viability assays exhibited reduced proliferation of activated lymph node cells when extracted from 2AG-treated EAE animals, whereas a dose-dependent response of activated lymphocytes to 2AG-treatment in vitro was noticed.CONCLUSION AND IMPLICATIONS: Our data indicate for the first time that 2AG treatment may provide direct (via CBRs) and immune (via M2 macrophages) mediated neuroprotection in EAE.

DOI10.1016/j.brainres.2011.03.020
Alternate JournalBrain Res.
PubMed ID21406188
Grant ListDA-9789 / DA / NIDA NIH HHS / United States

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.